Emily S Reisenbichler

List of Publications by Year
in descending order

38 papers	920 citations	623734 14 h-index	477307 29 g-index
39 all docs	39 docs citations	39 times ranked	1123 citing authors

#	Article	IF	Citations
1	Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+ breast cancer. Modern Pathology, 2022, 35, 44-51.	5.5	61
2	Stromal Changes are Associated with High P4HA2 Expression in Ductal Carcinoma in Situ of the Breast. Journal of Mammary Gland Biology and Neoplasia, 2022, 26, 367.	2.7	1
3	Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. JAMA Oncology, 2022, 8, 607.	7.1	147
4	Abstract P1-05-02: Intratumor molecular tumor heterogeneity in low ER-expressing primary breast tumors. Cancer Research, 2022, 82, P1-05-02-P1-05-02.	0.9	1
5	Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer. Clinical Cancer Research, 2022, 28, 2587-2597.	7.0	16
6	Determination of the number of observers needed to evaluate a subjective test and its application in two PDâ€Ł1 studies. Statistics in Medicine, 2022, 41, 1361-1375.	1.6	6
7	LMNAâ€NTRK1 rearranged mesenchymal tumor (lipofibromatosisâ€like neural tumor) mimicking pigmented dermatofibrosarcoma protuberans. Journal of Cutaneous Pathology, 2021, 48, 290-294.	1.3	9
8	Expression of lymphoid enhancer-binding factor 1Âin breast fibroepithelial lesions. Human Pathology, 2021, 108, 68-75.	2.0	0
9	Characteristics and Long-Term Risk of Breast Angiosarcoma. Annals of Surgical Oncology, 2021, 28, 5112-5118.	1.5	15
10	Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. Npj Breast Cancer, 2021, 7, 9.	5.2	35
11	HERâ€2/ neu â€positive breast cancer neoadjuvant chemotherapy response after implementation of 2018 ASCO/CAP focused update. Breast Journal, 2021, 27, 631-637.	1.0	2
12	Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study. Modern Pathology, 2021, 34, 2130-2140.	5.5	14
13	A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer. Cancers, 2021, 13, 4839.	3.7	18
14	Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study. Modern Pathology, 2020, 33, 354-366.	5.5	25
15	Current Procedural Terminology Coding in an Academic Breast Pathology Service. American Journal of Surgical Pathology, 2020, 44, 566-566.	3.7	0
16	The path to a better biomarker: application of a risk management framework for the implementation of PDâ€Ł1 and TILs as immunoâ€oncology biomarkers in breast cancer clinical trials and daily practice. Journal of Pathology, 2020, 250, 667-684.	4.5	142
17	Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer. Modern Pathology, 2020, 33, 1746-1752.	5.5	94
18	Reciprocal expression of Annexin A6 and RasGRF2 discriminates rapidly growing from invasive triple negative breast cancer subsets. PLoS ONE, 2020, 15, e0231711.	2.5	11

#	Article	IF	Citations
19	Association between low estrogen receptor positive breast cancer and staining performance. Npj Breast Cancer, 2020, 6, 5.	5.2	20
20	Interobserver variability in breast carcinoma grading results in prognostic stage differences. Human Pathology, 2019, 94, 51-57.	2.0	25
21	Differences in immunohistochemistry utilization by general and breast subspecialty pathologists at a large academic institution. Annals of Diagnostic Pathology, 2019, 42, 92-95.	1.3	1
22	Developmental disorders and malformations of the breast. Seminars in Diagnostic Pathology, 2019, 36, 11-15.	1.5	10
23	Intraoperative sentinel lymph node evaluation: Optimizing surgical pathology practices in an era of changing clinical management. Annals of Diagnostic Pathology, 2018, 33, 45-50.	1.3	4
24	Feasibility of the Less Is More Approach in Treating Low-Risk Ductal Carcinoma In Situ Diagnosed on Core Needle Biopsy: Ten-Year Review of Ductal Carcinoma In Situ Upgraded to Invasion at Surgery. Archives of Pathology and Laboratory Medicine, 2018, 142, 1120-1126.	2.5	17
25	Can tumor-associated macrophages in ductal carcinoma in situ on biopsy predict invasive carcinoma on excision?. Human Pathology, 2018, 82, 158-162.	2.0	5
26	Lack of MDM2 interpretation guidelines contribute to diagnostic difficulty in a case of undifferentiated sarcoma. Human Pathology: Case Reports, 2018, 13, 1-3.	0.2	2
27	Is tumor cellularity in primary invasive breast carcinoma of prognostic significance?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 611-617.	2.8	3
28	Protein Acyltransferase DHHC3 Regulates Breast Tumor Growth, Oxidative Stress, and Senescence. Cancer Research, 2017, 77, 6880-6890.	0.9	50
29	Reporting the greatest linear extent of ductal carcinoma in situ on needle core biopsy. Human Pathology, 2016, 50, 140-145.	2.0	3
30	MRI-Guided Breast Needle Core Biopsies: Pathologic Features of Newly Diagnosed Malignancies. Breast Journal, 2014, 20, 453-460.	1.0	8
31	The clinical use of a P63/cytokeratin7/18/cytokeratin5/14 antibody cocktail in diagnostic breast pathology. Annals of Diagnostic Pathology, 2014, 18, 313-318.	1.3	14
32	The Predictive Ability of a CK5/p63/CK8/18 Antibody Cocktail in Stratifying Breast Papillary Lesions on Needle Biopsy. American Journal of Clinical Pathology, 2013, 140, 767-779.	0.7	7
33	Interobserver Concordance in Implementing the 2010 ASCO/CAP Recommendations for Reporting ER in Breast Carcinomas. American Journal of Clinical Pathology, 2013, 140, 487-494.	0.7	53
34	Evaluation of Dual Immunohistochemistry and Chromogenic In Situ Hybridization for HER2 on a Single Section. American Journal of Clinical Pathology, 2012, 137, 102-110.	0.7	14
35	Luminal cytokeratin expression profiles of breast papillomas and papillary carcinomas and the utility of a cytokeratin 5/p63/cytokeratin 8/18 antibody cocktail in their distinction. Modern Pathology, 2011, 24, 185-193.	5.5	24
36	Non-Trophoblastic Tumors as Other Causes of Elevated Human Chorionic Gonadotrophin. Laboratory Medicine, 2010, 41, 183-183.	1.2	1

#	Article	IF	Citations
37	Î²eta-Human Chorionic Gonadotropin Production Associated with Phyllodes Tumor of the Breast: An Unusual Paraneoplastic Phenomenon. Breast Journal, 2009, 15, 527-530.	1.0	15
38	Multicomponent Lyme vaccine: Three is not a crowd. Vaccine, 2005, 23, 3687-3696.	3.8	46